Acadia Pharmaceuticals (ACAD) Operating Expenses (2010 - 2026)

Acadia Pharmaceuticals has reported Operating Expenses for 17 years, with the latest figure at $270.1 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 16.34% year-over-year to $270.1 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 34.55% increase from a year earlier, with the FY2025 full-year figure at $966.7 million, up 32.97% from the prior year.
• Operating Expenses was $270.1 million for Q2 2026 at Acadia Pharmaceuticals, down from $272.7 million in the prior quarter.
• The five-year high for Operating Expenses was $272.7 million in Q1 2026, with the low at $106.1 million in Q4 2024.
• Average Operating Expenses over 5 years is $209.8 million, with a median of $215.1 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses plunged 45.89% in 2024, then surged 151.27% in 2025.
• Over 5 years, Operating Expenses stood at $182.6 million in 2022, then increased by 7.42% to $196.1 million in 2023, then slumped by 45.89% to $106.1 million in 2024, then soared by 151.27% to $266.6 million in 2025, then gained by 1.32% to $270.1 million in 2026.
• The last three Operating Expenses figures came in at $270.1 million (Q2 2026), $272.7 million (Q1 2026), and $266.6 million (Q4 2025), per Business Quant data.